当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2016年第21期 > 正文
编号:12959105
冠状动脉支架内再狭窄患者的氯吡格雷抵抗及CYP2C19基因多态性分析(4)
http://www.100md.com 2016年7月25日 《中国医药导报》2016年第21期
     [17] 周健,康熙雄,吕红,等.中国健康人群与精神分裂症患者细胞色素P450 2C19/P450 2D6遗传多态性的比较[J].首都医科大学学报,2007,28(2):176-179.

    [18] Sim SC,Risinger C,Dahl ML,et al. A common novel CYP2C19 gene variant causes ultrarapid drug response to proton pump inhibitors and antidepressants [J]. Clin Pharmacol Ther,2006,79(1):103-113.

    [19] Davis EM,Knezevich JT,Teply RM. Advances in antiplatelet technologies to improve cardiovascular diease morbidity and mortality:areview of ticagrelor [J]. Clin Pharmacol,2013,5(Issue 1):67-83.

    [20] Mehta SR,Tanguay JF,Eikelboom JW,et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes(CURRENT-OASOS 7):a randomised factorial trial [J]. Lancet,2010,376(9748):1233-1243.

    [21] Solmaz H,Akbulut M,Korkmaz H,et al. Effects of high loading dose of clopidogrel in ST elevated myocardial infarction treated with fibrinolytic agent [J]. Clin Invest Med,2013,36(1):E18-E23.

    [22] Gao L,Wang F,Wang B,et al. Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression [J]. Pharmacol Exp Ther,2006,318(1):53-58.

    (收稿日期:2016-04-09 本文编辑:任 念) (刘丽媚 李雪锋 李存仁 古献芳 林斌 曾文峰)
上一页1 2 3 4